Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.

Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.

Item

http://www.wikidata.org/entity/Q34928256

Q34928256

about

Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis Is screening and surveillance for early detection of gastric cancer needed in Korean Americans?Kyoto global consensus report on Helicobacter pylori gastritis A review of the past, present, and future directions of neoplasia Coming of Age in the Life of Neoplasia: Where We Have Been and Where We Are Going Chronic gastritis.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portu Gastric cancer in a Caucasian population: role of pepsinogen C genetic variants.Screening for and surveillance of gastric cancer.Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.Health economic assessment for screening of gastric cancer in a high risk population in northeastern china.Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers.Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies.Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.Screening and Preventive Strategies in Esophagogastric Cancer.Pepsinogen-II 100 bp ins/del gene polymorphism and its elevated circulating levels are associated with gastric cancer, particularly with Helicobacter pylori infection and intestinal metaplasia.Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis.Decrease in PSCA expression caused by Helicobacter pylori infection may promote progression to severe gastritis.Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.Immune responses against Helicobacter pylori in gastric cancer patients and in risk groups for gastric cancer.Age-Specific Gastric Cancer Risk Indicated by the Combination of Helicobacter pylori Sero-Status and Serum Pepsinogen Levels.Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portug

P2860

Q26778122-0877982B-FC97-4ADB-A21D-F8DA798BDD22 Q26778331-EE32D7E7-0D31-4BC6-A6BB-36AB7B6FC4BC Q26799430-37BE3A31-620D-4C85-81A1-F914D9E9CC2D Q28389391-A26112C7-2FD5-48EE-858C-404490CAEFFC Q28389985-B868CEB8-64FD-4348-92CE-B1A2B9A373A4 Q28395095-04B48CC8-48F3-44BE-B01B-8DC29F02BE0D Q30374031-F4CA5637-D40F-4308-80FA-5E7A143953D2 Q30426539-E5EE79E5-81EA-4F32-92F5-D5711300092A Q33866182-ADD44C9D-C06F-4862-8F6B-AFC66FB16EE9 Q34326563-0E5B2F41-A0F7-4702-9463-E2ABDD885D9A Q34978232-6ABCEE0D-5799-4239-A060-38D64A4FBFA0 Q35755917-E0FC85E1-8FEE-42DD-9437-77459E29C1A7 Q36654631-4D00B296-F4BC-4509-ABEC-9439F2B22DAA Q36693173-CF14E7C1-1FA1-4A8D-9556-9BC0A4CCFED6 Q36996612-BE6964F0-45F2-4D6E-9DED-DF8827D78B3C Q38244069-ED96DFEE-5962-4E29-A7DC-3FF661BDBB70 Q39171528-8C366578-162F-4583-8B0E-83AEA72AD828 Q40943310-0F883B85-2001-47E9-8319-2693D239638C Q47106951-975B7C58-EC82-4304-A4C7-BDB233D44D66 Q47438971-FCB5A5D8-4BA7-4053-80A0-C90F7A97A216 Q49499639-5BF15C5C-2030-4F00-84EF-460C8720EF49 Q50465037-4C908F5D-3F19-427C-9F3E-2128BFE550A6 Q51303433-05AD664C-0557-47FB-96AD-346F2195B73D Q54858925-29FC3095-DD4C-48A8-90CA-F07C8AE65D13 Q55194995-B6FC1D66-93FB-4FF7-904C-D99C6906E2A4 Q57698678-C183BAAE-27B8-480E-8644-D73CA21B209D

P2860

Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.

Item

http://www.wikidata.org/entity/Q34928256

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu